Bristol-Myers Squibb (BMY) opened 2026 with Q1 revenue of US$11.5b, basic EPS of US$1.31 and net income of US$2.7b, setting the tone for how investors will judge its recent profitability. The company has seen quarterly revenue move from US$11.2b and basic EPS of US$1.21 in Q1 2025 to US$11.5b and US$1.31 in Q1 2026. Trailing twelve month EPS reached US$3.57, giving a clearer read on earnings power over the last year. With trailing net profit margin at 15% and recent earnings growth of 34.2% over the last twelve months, the latest print puts profitability squarely in focus for anyone tracking how durable those margins might prove to be.

See our full analysis for Bristol-Myers Squibb.

With the headline numbers on the table, the next step is to set them against the widely followed stories about Bristol-Myers Squibb to see which narratives are supported by the data and which ones start to look out of date.

Margins And Trailing Profits In Focus

• Over the last 12 months, Bristol-Myers Squibb generated US$48.5b in revenue and US$7.3b in net income, resulting in a 15% net profit margin, compared with 11.4% in the prior year and 34.2% year over year earnings growth.
• Bulls point to this margin profile as evidence of earnings strength, yet the data present a mixed picture:
  • Reported earnings growth of 34.2% and trailing EPS of US$3.57 line up with the bullish view that cost discipline and higher margin products can support stronger profits over time.
  • At the same time, analysts in the provided forecasts still expect earnings to decline by about 2.2% per year over the next three years, which sits awkwardly beside the recent margin improvement and is an important check on the most optimistic expectations.

Bulls argue that the recent margin uplift could be the start of a longer phase of stronger profitability, while skeptics focus on the forecast declines in revenue and earnings. This sets up a clear debate that you can weigh against the detailed bullish case in 🐂 Bristol-Myers Squibb Bull Case.

Earnings Growth Versus Bearish Revenue Concerns

• Trailing twelve month net income of US$7.3b sits alongside revenue forecasts that point to a 6.8% annual decline over the next three years, highlighting the gap between recent profit growth and expectations for shrinking sales.
• Bears highlight loss of exclusivity and pricing pressure as threats to revenue, and the provided figures give them some support as well as some pushback:
  • Forecast revenue declining 6.8% per year fits closely with the cautious view that top line pressure from patent expiries and pricing will weigh on the business even if margins hold up.
  • However, the 15% trailing margin and US$7.3b of profit show the company entering that period from a position of solid recent profitability, which challenges the idea that revenue pressure automatically translates into weak near term earnings power.

Skeptics see the projected revenue contraction as a key warning sign, while the current margin and profit levels show why the bearish case is far from one sided. This tension sits at the heart of the more cautious narrative in 🐻 Bristol-Myers Squibb Bear Case.

Valuation Gap And Dividend Yield

• Based on a share price of US$58.22, the data show a P/E of 16.3x versus 17x for the US Pharmaceuticals industry and 23.6x for peers, along with a DCF fair value of US$121.82 and a 4.33% dividend yield.
• Consensus narrative supporters often point to this combination of valuation and income, and the numbers illustrate why:
  • The P/E discount to peers and DCF fair value of US$121.82 both suggest the stock is priced below the level implied by those models, which aligns with views that the market is cautious relative to the company’s recent 15% margin and 34.2% earnings growth.
  • On the other hand, forecasts for earnings to decline 2.2% per year and revenue 6.8% per year, plus the presence of a US$6.6b one off loss and high debt, help explain why that apparent valuation gap and 4.33% yield may not be enough on their own for more conservative investors.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Bristol-Myers Squibb on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both optimism and concern in the figures so far, it makes sense to move quickly and test the story against the full set of facts using 4 key rewards and 3 important warning signs.

See What Else Is Out There

Forecast revenue and earnings declines, a US$6.6b one off loss and high debt all point to balance sheet pressure that some investors may want to sidestep.

If those red flags give you pause, compare this profile against companies in the solid balance sheet and fundamentals stocks screener (44 results) to focus on businesses with sturdier financial foundations and potentially steadier cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.